Clinical Trial Update: Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study of alisertib (MLN8237) in adults with aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and mantle cell lymphoma among ot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• T-cell Lymphoma
• Transformed Follicular Lymphoma

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-03-27